is the most common prototype of acute glomerulonephritis in children. APSGN is a classic example of acute glomerulonephritis, characterized by the sudden onset of gross hematuria, edema, hypertension and acute renal insufficiency. It may occur at any age, but it is more commonly encountered between the ages of 2 and 15 years (RodriguezIturbe 1994; Berrios et al. 2004 ). The onset of APSGN typically occurs 7-14 days after an upper respiratory tract infection, and as long as six weeks after impetigo (Vehaskari and Aviles 2007) . Due to oliguria or anuria and volume overload, severe edema may also be present.
Brain natriuretic peptide (BNP) is a cardiac natriuretic peptide hormone that is produced in both the brain and the heart (Levin et al. 1998; Hall 2004) . Its prohormone, proBNP, is cleaved to a biologically active form of BNP and an inactive N-terminal proBNP peptide (NT-proBNP). The inactive NT-proBNP can be detected and measured in the circulation (Gershwin et al. 2006) .
BNP is involved in fluid and electrolyte homeostasis during heart failure and is secreted predominantly from the ventricular myocardium. Myocyte stretch, increased enddiastolic pressure and volume in the left ventricle (LV) cause BNP to be released from ventricular myocytes (de Lemos et al. 2003) .
Higher NT-proBNP concentrations in diseases associated with left ventricular volume overload (congenital heart disease with left-to-right shunt, patent ductus arteriosus) have been reported previously in different studies (Puddy et al. 2002; Suda et al. 2003; Nir et al. 2004) . However, to our knowledge, no previous studies have examined the link between plasma NT-proBNP levels and APSGN in children.
The aim of this study was to investigate the relationship between NT-proBNP and the echocardiographic and clinical findings of patients with APSGN.
MATERIALS AND METHODS
The study group consisted of 28 patients with APSGN (17 boys and 11 girls; ages between 4 and 14 years). All patients were presented to our clinic for macroscopic or microscopic hematuria, casts on urinalysis, edema, hypertension, oliguria or anuria and renal insufficiency. The diagnosis of APSGN was made by clinical history, physical examination and supporting evidence of recent streptococcal infection, a positive ASO titer with associated hypocomplementemia.
A detailed health history was obtained, and thorough physical examination and routine laboratory tests were performed in all patients. The following laboratory tests (complete blood count, biochemical analyses including plasma electrolytes, urea, creatinine, uric acid, total protein, albumin, total cholesterol and triglycerides, plasma complements 3 and 4, urinalysis, urine protein/creatinine ratio, throat culture, ASO titer) were performed and the results of the follow-up examinations were recorded.
The control group consisted of 26 age-and gender-matched children (16 boys and 10 girls; ages between 5 and 14 years). The control group was selected from healthy children among those evaluated for elective surgery or routine checkup. They had normal cardiac and renal function, and had not received any treatment affecting the heart, kidneys or the fluid balance before and throughout the study period. All the parents of participant children provided their informed consents before the study.
Venous blood samples from all subjects were obtained for biochemical measurements and NT-proBNP. Biochemical measurements, including plasma electrolytes, urea and creatinine, were determined by autoanalyzer (Abbott Aeroset, Japan). NT-proBNP levels, telecardiogram, electrocardiogram and echocardiogram for cardiac evaluation were performed in both patient and control groups on admission, then only in the patient group two weeks later.
Measurement of NT-pro BNP levels
Three milliliters of blood were drawn into tubes containing sodium ethylene diamino tetra acetate (EDTA) and aprotinin while the patient was resting in the supine position. Immediately, the blood was centrifuged at 4ºC and plasma was separated. Plasma then was stored at -20ºC until additional processing. Plasma NT-proBNP level was measured with electro-chemiluminescence immunoassay using an immunoassay analyzer (Roche Elecsys 1010 or Modular Analytics E170, Indianapolis, USA). No hemolyzed or EDTA-treated samples were included.
Echocardiography
Patients were simultaneously evaluated with 2-dimensional echocardiogram. Pulsed-wave Doppler and M-mode echocardiography were performed by a cardiologist, with a Hewlett Packard Sonos vingmed system five machine using a 5-MHz transducer. M-mode measurements were performed according to the recommendations of the American Society of Echocardiography. The LV fractional shortening (FS) and ejection fraction (EF) were calculated by Teich formula. The LV systolic functions were considered abnormal when EF was less than 60% or FS less than 30%. Doppler signals were recorded from the apical 4-chamber view with a 3-5 mm sample volume placed at the level of mitral leaflet tips parallel to maximal mitral inflow. The midpoints of the darkest portion of the Doppler velocity waveforms were digitized, and the following indices were calculated: 1. peak flow velocity of early LV filling (peak E); 2. peak flow velocity of late (atrial) LV filling (peak A); 3. ratio of peak early to peak late flow velocities (E/A ratio), and 4. isovolumic relaxation time (IVRT). The examinations and evaluations were performed by the same physician.
Statistical analysis
Data with metric values were expressed as means ± standard deviations. Statistical differences between the patient and control groups were evaluated using Student's t test. The results were considered statistically significant if the p values were less than 0.05.
RESULTS
A total of 28 patients with APSGN and 26 healthy subjects, who were admitted to our Hospital between September 2007 and March 2008, were enrolled in this study. The mean age of the study group was 8.2 ± 2.9 years (range 4-14 years) and that of the control group was 8.7 ± 3.0 years (range 5-14 years). The mean ages of patient and control groups were similar ( p > 0.05). Male to female ratio of the patients and controls were 1.54 and 1.60, respectively ( p > 0.05). The mean height and weight of patients and control groups were 125.2 ± 18.5 cm, 28.4 ± 10.8 kg, and 124.4 ± 23.1 cm, 26.3 ± 12.1 kg, respectively ( p > 0.05).
Clinical and laboratory features of patients with APSGN are shown in Table 1 . Periorbital edema, oliguria, hypertension (> 90-95th percentile systolic or diastolic pressure adjusted for gender, age and height) and microscopic hematuria were detected in all patients. Mild lower extremity edema was detected in 16 patients, macroscopic hematuria in 14, severe edema and severe hypertension (> 99th percentile systolic or diastolic pressure adjusted for gender, age and height) in six, anuria in three and hypertensive encephalopathy in one.
Plasma NT-proBNP levels were significantly higher in the patient group than the control group before the therapy (diuretic treatment) ( p < 0.001) ( Table 2) .
Cardiac changes were determined by echocardiography, and left ventricular dysfunction was detected in six patients on admission (Table 3) . Severe edema, severe hypertension (mean 151.0 ± 11.0 mmHg) and increased plasma NT-proBNP levels were also determined in these same six patients (n = 6). Furthermore, NT-proBNP levels were higher in these six patients with respect to the patients with mild forms of APSGN (n = 22) ( p = 0.003) ( Table 3 ). The changes in systolic and diastolic echocardiographic parameters of patients and controls are shown in Table 4 .
The means of systolic echocardiographic parameters (left ventricular ejection, fractional shortening) were lower in all patients with APSGN than they were in control subjects, but the differences were not statistically significant ( p > 0.05). Left ventricular end diastolic diameter (LVEDd) measurement was higher in the patient group with respect to the control group, but this also was not statistically significant ( p > 0.05) ( Table 5 ).
In the follow-up period, plasma NT-proBNP levels of all the patients were decreased and echocardiographic changes were found to be normal in 26 patients after two weeks. NT-proBNP levels and left ventricular dysfunction of two patients who had severe clinical findings were detected within normal limits four weeks later. Two weeks after admission, biochemical results, including plasma electrolytes, urea (29.9 ± 6.8 mg/dL) and creatinine levels (0.5 ± 0.17 mg/dL) were normal in all patients. Diuretic treatment significantly reduced the elevated NT-proBNP levels in the APSGN group. After diuretic treatment, NT-proBNP levels in the APSGN group were not comparable with the control group. The levels of NTproBNP in the patient group and the control group were 91.1 ± 54.3 pg/mL (range 28-209) and 69.5 ± 22.2 pg/mL (range 13-98) respectively ( p > 0.05) after treatment, but in patients with left ventricular dysfunction (n = 6), NTproBNP levels were found to be moderately decreased (171.5 ± 42.8 pg/mL).
Diuretics were used for edema in all patients. The patients (n = 6) with very high plasma NT-proBNP levels and left ventricle dysfunction required additional drug (enalapril and/or nifedipin) for edema and hypertension, and these drugs were given for 4-6 weeks compared with other patients (n = 22). No complications were detected in any patients.
DISCUSSION
BNP is mainly released from the ventricles in response to volume expansion and pressure overload, and thus, elevated end-diastolic pressure (Levin et al. 1998) . Plasma levels of natriuretic peptides are increased in patients with severe heart failure and NT-proBNP is a more sensitive measure for the detection of LV dysfunction (Cowie et al. 1997 ). The main stimuli for the synthesis and secretion of Patients with APSGN (n = 28)
NT-pro BNP (pg/mL)* 8876.2 ± 9650.8 69.5 ± 22.2
Significant difference between patients and control group, *p < 0.001 TABLE 3. Plasma NT-pro BNP levels of patients with mild f o r m s o f A P S G N a n d p a t i e n t s w i t h LV dysfunction (mean ± S.D.)
Patients with LV dysfunction (n = 6)
Patients with mild forms of APSGN (n = 22)
NT-pro BNP (pg/mL)* 22023.8 ± 4362.8 5438.4 ± 7445.5
Significant difference between patients and control group, *p < 0.003 Significant difference between patients and control group, *p < 0.001 proBNP are increased ventricular end diastolic pressure and ventricular wall tension (Hall 2004) . BNP is released in response to hypervolemia and is predominantly secreted from the ventricles (Gershwin et al. 2006) . APSGN resolves rapidly and has an excellent prognosis. However, APSGN may also present with one or more of its complications, such as profound volume expansion with heart failure. The presentation of APSGN varies according to disease severity. Pulmonary edema and heart failure due to fluid overload may be present in moderately severe cases (Vehaskari and Aviles 2007) . BNP and NTproBNP levels at rest are related to LV dimensions, volumes, function and mass (Kotaska et al. 2006) . Correlation between BNP levels and increasing pulmonary pressure, pulmonary resistance or the end-diastolic volume has also previously been reported (Koch et al. 2006 ). Higher natriuretic peptide levels have been reported in the conditions with marked atrial distension, left ventricular overload, leftto-right shunt and pulmonary hypertension and the increased plasma BNP and NT-proBNP concentrations in diseases associated with left ventricular volume overload (congenital heart disease with left-to-right shunt, patent ductus arteriosus) have also been reported in different studies (Nir et al. 2004; Puddy et al. 2002; Suda et al. 2003) .
In the present study, plasma NT-proBNP levels were found to be higher in the patient group (n = 28) than in the control group. We found significant increases in NT-proB-NP levels in patients with left ventricle dysfunction (n = 6) who presented with severe symptoms (severe edema, severe hypertension). NT-proBNP levels were higher in these patients (n = 6) with respect to the other patients (n = 22) and the difference was statistically significant ( p = 0.003).
Although the differences between systolic and diastolic echocardiographic changes of patients with APSGN and controls were not statistically significant, the NT-proBNP levels of patients were significantly higher than controls upon admission. At the end of the two weeks, NT-proBNP levels of the patients were observed to have decreased and the difference between NT-proBNP levels of the patients and control group was no longer statistically significant ( p > 0.05). High levels of NT-proBNP in patients may be due to volume overload caused by APSGN, which is not related to primary cardiac dysfunction. However, in the present study, we were unable to evaluate a cut off level for NT-por BNP levels, which may be indicative and used as an indicator of specific cardiac and/or volume disturbance.
In conclusion, these findings suggest that the levels of NT-proBNP may be associated with the severity of left ventricular dysfunction and volume overload in patients with APSGN. The plasma NT-proBNP levels may be a useful marker to assess the cardiac evaluation and volume overload in the follow up of selected APSGN patients with severe symptoms. We believe that further studies are necessary to identify the significance of plasma NT-proBNP levels in patients with APSGN before its routine clinical use.
